{"id":"W4404910188","doi":"10.1016/s1470-2045(24)00673-9","title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation; Novartis","keywords":"Fulvestrant; Medicine; Aromatase inhibitor; Internal medicine; Oncology; Breast cancer; Cancer; Cohort; Regimen; Letrozole; Clinical endpoint; Clinical trial; Aromatase; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007599575,0.000497064,0.002050877,0.0002177092,0.00008267037,0.00004594076,0.0005221373,0.0001774637,0.0003321127],"category_scores_gemma":[0.00003064332,0.000363483,0.0000838632,0.0009112676,0.0004961573,0.0004093293,0.0002843588,0.0009200115,0.00005765725],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001417674,"about_ca_system_score_gemma":0.0009330881,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001052851,"about_ca_topic_score_gemma":0.001538905,"domain_scores_codex":[0.9965755,0.0004479014,0.000871974,0.0008533754,0.0004533746,0.0007979279],"domain_scores_gemma":[0.9981213,0.0004243607,0.0002902427,0.0006615269,0.0003108766,0.0001917435],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.348076,0.0301267,0.01189396,0.0006788081,0.006284188,0.002768998,0.1042574,0.001114079,0.3129496,0.0001944111,0.002151211,0.1795046],"study_design_scores_gemma":[0.4445218,0.03004186,0.4173527,0.006965886,0.003178994,0.001176497,0.04175485,0.0106016,0.02500801,0.000402017,0.01643711,0.002558762],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9811374,0.005904372,0.0002162868,0.004477678,0.0005528246,0.005684184,0.0007765598,0.0001030123,0.001147673],"genre_scores_gemma":[0.9929611,0.0007683119,0.002147927,0.0007715742,0.0006929705,0.002232014,0.00006139775,0.00007867787,0.0002860082],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4054587,"threshold_uncertainty_score":0.9998817,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04917139460894078,"score_gpt":0.4071316979650551,"score_spread":0.3579603033561143,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}